New hope for bile duct cancer? keytruda and lenvima combo tested

NCT ID NCT04550624

Completed Disease control Sponsor: Shanghai Jiahui International Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of two drugs, pembrolizumab (Keytruda) and lenvatinib (Lenvima), in 27 people with advanced biliary tract cancer that had worsened after standard treatment. The goal was to see if the combination could shrink tumors. The study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (Keytruda) and lenvatinib (Lenvima)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced biliary tract cancer who have run out of standard therapies.
What could go wrong: This is a small, early-phase study with only 27 participants, so results may not apply to everyone. The combination may cause significant side effects and may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BILIARY TRACT CARCINOMA

Contacts and locations

Locations

Shanghai Jiahui International Hospital

Shanghai, Shanghai Municipality, 200233, China
Shanghai Zhongshan Hospital

Shanghai, Shanghai Municipality, 200233, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.